OBJECTIVE: Thromboembolic disorders are leading causes of morbidity and mortality, with treatment and prophylaxis a priority. There has been a heavy dependency upon warfarin and heparin for anticoagulation for 60 years. This is likely to change with the emergence of novel oral anticoagulants. CONCLUSION: Interventional radiologists are increasingly encountering these medications, and a thorough knowledge of them is essential for appropriate periprocedural management. This article will review these novel agents, their uses, and their pharmacologic profiles and will propose guidelines for periprocedural management.
OBJECTIVE:Thromboembolic disorders are leading causes of morbidity and mortality, with treatment and prophylaxis a priority. There has been a heavy dependency upon warfarin and heparin for anticoagulation for 60 years. This is likely to change with the emergence of novel oral anticoagulants. CONCLUSION: Interventional radiologists are increasingly encountering these medications, and a thorough knowledge of them is essential for appropriate periprocedural management. This article will review these novel agents, their uses, and their pharmacologic profiles and will propose guidelines for periprocedural management.
Authors: J Scott Kriegshauser; Howard H Osborn; Sailen G Naidu; Eric A Huettl; Maitray D Patel Journal: J Clin Med Date: 2018-04-20 Impact factor: 4.241